vimarsana.com

Versiti Blood Research Institute News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Ponatinib Showcases Long-Term Efficacy, Safety in CP-CML With T315I Mutations

Ponatinib generated long-term efficacy and displayed manageable safety in chronic-phase chronic myeloid leukemia harboring a T315I mutation.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.